Safety and efficacy of oral anticoagulants therapies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis
Background: Different antithrombotic treatments, from vitamin K antagonists to direct oral
anticoagulants (DOACs), are available to reduce ischemic risks in patients with atrial …
anticoagulants (DOACs), are available to reduce ischemic risks in patients with atrial …
Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world …
SV Ramagopalan, A Sicras-Mainar… - Journal of …, 2019 - becarispublishing.com
Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …
The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany
S Hofmann, S Himmler, D Ostwald… - Journal of …, 2020 - becarispublishing.com
In this study, we assessed the productivity gains associated with the use of obinutuzumab in
combination with chemoimmunotherapy (G-chemo) in first-line treatment among follicular …
combination with chemoimmunotherapy (G-chemo) in first-line treatment among follicular …
Anticoagulation in atrial fibrillation patients
P Magnusson, JV Pergolizzi Jr, RK Wolf… - … and Treatment of …, 2019 - books.google.com
Atrial fibrillation (AF) is the most common arrhythmia and may cause thromboembolic
events, typically stroke. Advances in pharmacological approaches to anticoagulation and …
events, typically stroke. Advances in pharmacological approaches to anticoagulation and …